Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

HYG (iShares iBoxx $ High Yield Corporate Bond ETF) trades at $77.115, down 0.08% with a bearish technical signal from moving averages. The fund has shown unusual options activity recently amid a challenging bond market environment where Treasury yields have reached multi-year highs. Recent dividend payments of $0.34-$0.44 per share provide income support, but the overall technical picture remains weak with significant selling pressure.

The outlook for HYG remains challenged by rising interest rates and bond market volatility. While the fund offers attractive yield income through regular dividends, the bearish technical momentum and elevated Treasury yields create headwinds for price appreciation. Key risks include further rate hikes and credit spread widening in the high-yield bond market.